Teva and Sanofi reported durable 44-week efficacy for duvakitug in inflammatory bowel disease, while the FDA accepted Teva's application for TEV-749, a once-monthly olanzapine injection for schizophrenia.
Abivax announced novel preclinical and clinical data for obefazimod at ECCO 2026, highlighting anti-fibrotic potential in Crohn's disease, favorable safety profile, and rapid onset of symptomatic relief in inflammatory bowel disease patients.
Teva and Sanofi reported positive 44-week data from the RELIEVE UCCD long-term extension study of duvakitug, showing durable efficacy in ulcerative colitis and Crohn's disease patients.
New data from LIBERTY studies show subcutaneous infliximab effectively restored and maintained disease control in Crohn's disease and ulcerative colitis patients after drug holiday of 16 weeks or more, with sustained efficacy through Week 102.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03498625 |
Crohn's Disease Endoscopic REmission Definition in an Objective Way |
COMPLETED | NA |
| NCT03487900 |
Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD Patients in Clinical Remission at Baseline, Predictive of Sustained Clinical Remission Using a 2-year Follow up |
UNKNOWN | NA |
| NCT03306446 |
Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab |
UNKNOWN | PHASE4 |
| NCT02856763 |
Predictive Factors of ANTI-TNF Response in Luminal Crohn's Disease Complicated by Abscess |
COMPLETED | |
| NCT01757964 |
Bacteriotherapy in Pediatric Inflammatory Bowel Disease |
COMPLETED | PHASE1 |
